{
  "nct_id": "VT3996-301",
  "age": "Adults",
  "cancer_center_accrual_goal_upper": 0,
  "data_table4": "Interventional",
  "drug_list": {
    "drug": [
      {
        "drug_name": "Nanatinostat"
      },
      {
        "drug_name": "Valganciclovir"
      }
    ]
  },
  "long_title": "An Open-Label, Multicenter Phase 1b/2 Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors and in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma",
  "management_group_list": {
    "management_group": [
      {
        "is_primary": "Y",
        "management_group_name": "HKUMed"
      }
    ]
  },
  "oncology_group_list": {
    "oncology_group": [
      {
        "group_name": "Group 1",
        "is_primary": "N"
      }
    ]
  },
  "phase": "1b/23",
  "principal_investigator": "Dr. Victor LEE",
  "program_area_list": {
    "program_area": [
      {
        "is_primary": "Y",
        "program_area_name": "Program 1"
      }
    ]
  },
  "protocol_id": null,
  "protocol_no": "",
  "protocol_target_accrual": 0,
  "protocol_type": "",
  "prior_treatment_requirements": [
    "Histologically or cytologically documented EBV+ tumor cells by EBER-ISH or LMP-1 per an archival tumor sample taken within 2 years prior to screening, otherwise a de novo biopsy is required.",
    "Patients with recurrent or metastatic nasopharyngeal carcinoma (RM-NPC) (excluding patients in the Phase 1b exploratory proof-of-concept cohort) for whom no potentially curative options are available, who have received at least 1 prior line of platinum-based chemotherapy and no more than 3 prior lines of therapy."
  ],
  "short_title": "Study of Nanatinostat and Valganciclovir in Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors",
  "site_list": {
    "site": []
  },
  "sponsor_list": {
    "sponsor": []
  },
  "staff_list": {
    "protocol_staff": []
  },
  "status": "open to accrual",
  "summary": "",
  "treatment_list": {
    "step": [
      {
        "arm": [
          {
            "arm_code": "Arm A",
            "arm_internal_id": 1111,
            "arm_description": "Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors",
            "arm_suspended": "N"
          },
          {
            "arm_code": "Arm B",
            "arm_internal_id": 2222,
            "arm_description": "Patients with Advanced Epstein-Barr Virus-Positive (EBV+) Solid Tumors in Combination with Pembrolizumab in Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma",
            "arm_suspended": "N"
          }
        ],
        "step_code": "1",
        "step_type": "Registration",
        "step_internal_id": 1111,
        "match": [
          {
            "and": [
              {
                "clinical": {
                  "oncotree_primary_diagnosis": "Nasopharyngeal Carcinoma",
                  "disease_status": [
                    "Recurrent",
                    "Metastatic"
                  ]
                }
              }
            ]
          }
        ]
      }
    ]
  }
}